{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:40:19Z","timestamp":1791945619661,"version":"4.3.4"},"reference-count":48,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100001868","name":"National Science Council","doi-asserted-by":"publisher","award":["MOST110-2314-B-038-072-MY3"],"award-info":[{"award-number":["MOST110-2314-B-038-072-MY3"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001868","name":"National Science Council","doi-asserted-by":"publisher","award":["MOST111-2314-B-038-065-MY3"],"award-info":[{"award-number":["MOST111-2314-B-038-065-MY3"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022600","name":"Wan Fang Hospital","doi-asserted-by":"publisher","award":["112-wf-eva-31, 113-wf-eva-06, 114-wf-eva-23"],"award-info":[{"award-number":["112-wf-eva-31, 113-wf-eva-06, 114-wf-eva-23"]}],"id":[{"id":"10.13039\/501100022600","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Antipsychotic treatment is commonly associated with hyperprolactinemia, leading to menstrual disturbances, sexual dysfunction, and decreased bone mineral density. Nearly all antipsychotic drugs can elevate prolactin levels, affecting up to 70% of patients with schizophrenia. We aim to evaluate the potential therapeutic role of metformin in reducing hyperprolactinemia among these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We systematically searched PubMed, CNKI, Embase, Cochrane, and Web of Science through January 31, 2024, for randomized controlled trials (RCTs) evaluating metformin\u2019s effect on prolactin levels in patients with schizophrenia. Data were extracted and synthesized using random-effects meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      This meta-analysis included 10 RCTs with 1046 participants (584 received metformin and 462 received placebo or no treatment). Metformin significantly reduced prolactin levels compared to control groups (SMD\u2009=\u2009\u22120.98, 95% CI: \u22121.62, \u22120.35,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002; transformed MD\u2009=\u2009\u221234.88\u2009ng\/mL, 95% CI: \u221257.65, \u221212.46). Subgroup analyses indicated that higher doses (1500\u2009mg), shorter treatment durations (&lt;24\u2009weeks), higher BMI (&gt;25\u2009kg\/m\u00b2), and longer illness duration (&gt;1\u2009year) were associated with more significant prolactin reductions. Metformin was well tolerated with no significant increase in adverse events or all-cause discontinuation rates compared to the control group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This meta-analysis suggests that metformin shows potential as a treatment for antipsychotic-induced hyperprolactinemia, with a favorable tolerability profile in patients with schizophrenia, particularly at higher doses, shorter treatment durations, higher BMI, and longer illness duration. Despite the robustness of the findings, high heterogeneity necessitates cautious interpretation. Future research should explore demographic and clinical factors influencing the response to metformin for optimizing treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811251326945","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T11:37:48Z","timestamp":1742902668000},"page":"815-824","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating the efficacy of metformin in reducing hyperprolactinemia among patients with schizophrenia: A meta-analysis of randomized controlled trials"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2677-3944","authenticated-orcid":false,"given":"Kah Kheng","family":"Goh","sequence":"first","affiliation":[{"name":"Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"},{"name":"Psychiatric Research Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan"},{"name":"Department of Psychiatry, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan"},{"name":"Graduate Institute of Injury Prevention and Control, College of Public Health, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hsin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"},{"name":"Psychiatric Research Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan"},{"name":"Department of Psychiatry, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8281-8193","authenticated-orcid":false,"given":"Mong-Liang","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"},{"name":"Psychiatric Research Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan"},{"name":"Department of Psychiatry, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"e_1_3_2_2_1","article-title":"Hyperprolactinemia in adults treated with anti-psychotic drugs attending tertiary hospitals in Oman: An observational study","volume":"14","author":"Al Harthi MS","year":"2022","unstructured":"Al Harthi MS, Al Ghafri TS, Al Wasify L, et al. (2022) Hyperprolactinemia in adults treated with anti-psychotic drugs attending tertiary hospitals in Oman: An observational study. Cureus 14: e21532.","journal-title":"Cureus"},{"key":"e_1_3_2_3_1","first-page":"1130","article-title":"A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents","volume":"29","author":"Arman S","year":"2008","unstructured":"Arman S, Sadramely MR, Nadi M, et al. (2008) A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Med J 29: 1130\u20131134.","journal-title":"Saudi Med J"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2015.02.002"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1215807"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.1.64"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(81)90078-0"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107078281"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228648"},{"key":"e_1_3_2_10_1","first-page":"163","article-title":"Consensus on the management of antipsychotic-induced hyperprolactinemia","volume":"54","author":"Dengtang L","year":"2021","unstructured":"Dengtang L, Kaida J (2021) Consensus on the management of antipsychotic-induced hyperprolactinemia. Chin J Psychiatry 54: 163\u2013169.","journal-title":"Chin J Psychiatry"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2018.09.035"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4730-6"},{"key":"e_1_3_2_13_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Higgins J","year":"2011","unstructured":"Higgins J, Green S (eds) (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. London, UK: The Cochrane Collaboration."},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/00048674.2011.589044"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2017.02.010"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.699"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-0785-y"},{"key":"e_1_3_2_19_1","first-page":"156","article-title":"The effect of long term administration of metformin on prolactin level and C-reactive protein in newly diagnosed women with type II diabetes mellitus","volume":"4","author":"Khalaf B","year":"2015","unstructured":"Khalaf B (2015) The effect of long term administration of metformin on prolactin level and C-reactive protein in newly diagnosed women with type II diabetes mellitus. World J Pharmacol Pharmac Sci 4: 156\u2013169.","journal-title":"World J Pharmacol Pharmac Sci"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4530(02)00128-2"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12113769"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13470"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43440-023-00556-3"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2016.01.015"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0428-2"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1048"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-122224"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13307"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-0921-6420"},{"key":"e_1_3_2_30_1","first-page":"1034","article-title":"[The effects of risperidone combined with metformin on serum TSH, PRL, sICAM-1 levels, and daily living abilities in patients with schizophrenia]","volume":"27","author":"Lu Q","year":"2018","unstructured":"Lu Q (2018) [The effects of risperidone combined with metformin on serum TSH, PRL, sICAM-1 levels, and daily living abilities in patients with schizophrenia]. Henan Med Res 27: 1034\u20131035.","journal-title":"Henan Med Res"},{"key":"e_1_3_2_31_1","first-page":"56","article-title":"Prolactin elevation with antipsychotic medications: Mechanisms of action and clinical consequences","volume":"63","author":"Maguire GA","year":"2002","unstructured":"Maguire GA (2002) Prolactin elevation with antipsychotic medications: Mechanisms of action and clinical consequences. J Clin Psychiatry 63: 56\u201362.","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1976.01770030003001"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yfrne.2017.02.003"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000051263"},{"key":"e_1_3_2_35_1","first-page":"2984","article-title":"[Therapeutic effects of aripiprazole and metformin on hyperprolactinemia caused by amisulpride medication]","volume":"40","author":"Pan X","year":"2018","unstructured":"Pan X, Ju M, Wu J, et al. (2018) [Therapeutic effects of aripiprazole and metformin on hyperprolactinemia caused by amisulpride medication]. Hebei Med J 40: 2984\u20132986.","journal-title":"Hebei Med J"},{"key":"e_1_3_2_36_1","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: A comprehensive review","volume":"28","author":"Peuskens J","year":"2014","unstructured":"Peuskens J, Pani L, Detraux J, et al. (2014) The effects of novel and newly approved antipsychotics on serum prolactin levels: A comprehensive review. CNS Drugs 28: 421\u2013453.","journal-title":"CNS Drugs"},{"key":"e_1_3_2_37_1","first-page":"633","article-title":"[Metformin on sex hormones and menstruation in schizophrenics with olanzapine-induced obesity and amenorrhea]","volume":"46","author":"Qiang L","year":"2019","unstructured":"Qiang L, Chen F, Zhong A, et al. (2019) [Metformin on sex hormones and menstruation in schizophrenics with olanzapine-induced obesity and amenorrhea]. J Int Psychiatry 46: 633\u2013636.","journal-title":"J Int Psychiatry"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.4103\/japtr.JAPTR_65_19"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059202"},{"key":"e_1_3_2_41_1","first-page":"156","article-title":"[Research on treatment of glucose and lipid metabolism disorder in patients with Quetiapine-induced schizophrenia with Metformin]","volume":"23","author":"Wang Y-G","year":"2016","unstructured":"Wang Y-G, Huang L-G (2016) [Research on treatment of glucose and lipid metabolism disorder in patients with Quetiapine-induced schizophrenia with Metformin]. China Modern Med 23: 156\u2013159.","journal-title":"China Modern Med"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2012.11091432"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.718800"},{"key":"e_1_3_2_44_1","first-page":"417","article-title":"[Efficacy of metformin combined behavior intervention in the treatment of metabolic disorders caused by risperidone]","volume":"27","author":"Xia J-X","year":"2011","unstructured":"Xia J-X, Wang Y-B, Gan J-G, et al. (2011) [Efficacy of metformin combined behavior intervention in the treatment of metabolic disorders caused by risperidone]. Chin J Clin Pharmacol 27: 417\u2013419.","journal-title":"Chin J Clin Pharmacol"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000392"},{"key":"e_1_3_2_46_1","article-title":"[A controlled study on the metabolic effects of metformin in first-episode schizophrenia patients with risperidone treatment]","volume":"20","author":"Zhou J-Q","year":"2014","unstructured":"Zhou J-Q, Dong Z-W, Zhou X, et al. (2014) [A controlled study on the metabolic effects of metformin in first-episode schizophrenia patients with risperidone treatment]. Chin J Drug Abuse Prevent Treat 20: 144\u2013147+154.","journal-title":"Chin J Drug Abuse Prevent Treat"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.892477"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1034004"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.08.023"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251326945","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811251326945","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251326945","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:12:07Z","timestamp":1777507927000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811251326945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1177\/02698811251326945"],"URL":"https:\/\/doi.org\/10.1177\/02698811251326945","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]}}}